Vivani Medical announced proof-of-concept data for a subdermal exenatide implant designed for feline obesity and diabetes, which was published in BMC Veterinary Research.
Ricks highlighted that the company is trying to prove the efficacy of its drugs for not only weight loss but also obesity-driven diseases such as heart risks, diabetes, and sleep apnea.
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.
Elon Musk predicts that Novo Nordisk's weight-loss drug Ozempic will eventually become very cheap, following its depiction in a new South Park special as a luxury medication accessible only to the wealthy.
Eli Lilly has significantly increased its investment in its Lebanon, Indiana, manufacturing site to $9 billion, aiming to enhance production of tirzepatide injections.
CVS Health seeks a private equity partner to fund the expansion of Oak Street Health, acquired for $10.6 billion. This joint venture aims to open new clinics, easing initial losses and protecting CVS's financial health.